This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Minimal change disease (MCD) is the etiology of 10%–25% of cases of nephrotic syndrome in adults. The mainstay of treatment for adult MCD, oral gucocorticoids, is based on two randomized controlled trials and extensive observational data in adults, and this treatment leads to remission in over 80% of cases. Relapses are common, and some patients become steroid-resistant (SR), steroid-dependent (SD), or frequently relapsing (FR). The data guiding the treatment of these patients are limited. Here, we review MCD in adults with particular focus on the evidence for immunosuppressive therapy in these patients.
- Copyright © 2013 by the American Society of Nephrology
In this issue
Jump to section
- Article
- Abstract
- Pathophysiology
- Clinical Presentation
- Treatment of Initial Episode of MCD with Corticosteroids
- Alternative Regimens for the Initial Episode
- Corticosteroid-Resistant MCD
- Relapse of MCD
- Treatment of FR, SD, and Steroid-Resistant MCD
- Other Treatment Considerations in MCD
- Conclusion
- Disclosures
- Footnotes
- References
- Figures & Data
- Info & Metrics
More in this TOC Section
Up Front Matters
Cited By...
- Podocyte injury elicits loss and recovery of cellular forces
- Minimal change disease with maximum immunosuppression: successful treatment of steroid-dependent minimal change disease with rituximab
- Tacrolimus Monotherapy after Intravenous Methylprednisolone in Adults with Minimal Change Nephrotic Syndrome
- Minimal Change Disease
- Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature
- Comparison of Methylprednisolone Plus Prednisolone with Prednisolone Alone as Initial Treatment in Adult-Onset Minimal Change Disease: A Retrospective Cohort Study
- American Society of Nephrology Quiz and Questionnaire 2013: Glomerulonephritis